Endocrine Abstracts

Objective: To analysis the clinical pathological characteristics and ¹³¹I curative responses of familial differentiated thyroid cancer(FDTC) and sporadic differentiated thyroid cancer(SDTC).

Methods: A total of 112 FDTC patients(79 females, 33males, age(41.3±15.6)) and 1000 SDTC (658 females, 342males, (44.2±13.9)) who underwent ¹³¹I therapy in Department of Nuclear Medicine in our hospital between January 2011 and July 2021 were retrospectively enrolled. The clinical pathological characteristics, preablative stimulated thyroglobulin (ps-Tg), preablative stimulated thyroglobulin antibody(ps-TgAb) and response to the ¹³¹ I therapy (excellent response, indeterminate response, biochemical incomplete response, structural incomplete response) of two groups were analyzed and compared. The clinical pathological parameters included age, gender, pathological type, tumour maximum diameter, bilateral, multifoci, nodules goiter, thyroiditis membrane invasion, lymph node metastasis(LNM), invasion of the surrounding soft tissues, distant metastasis, TNM staging and ATA risk stratification (low-risk, intermediate-risk, high-risk). χ²test or Fisher exact test and independent-sample t test were used to compare the data between the two groups.

Results: Comparing the SDTCgroup, FDTC group showed higher proportion of bilateral foci (60.71%(68/112) vs 38.10%(381/1000), χ²=10.899, P<0.001); thyroiditis membrane invasion 45.53%(51/112) vs 25.90%(259/1000), χ²=9.899, P<0.01; distant metastasis:13.39%(15/112) vs 6.00%(6/1000). There was a ststistical difference in risk stratification between two groups (high-risk: 17.86%(20/112) vs 9.20%(92/1000), intermediate-risk: 67.85%(76/112) vs 73.00%(730/1000), low-risk: 14.28%(16/112) vs 17.80%(178/1000), χ²=6. 989, P<0.01). The response to ¹³¹I therapy of SDTC group were higher than that of the FDTC group(t=-2.275, P<0.05)There were no significant differences in other clinical pathological parameters and ps-Tg and between FDTC group and SDTC group (all p>0.05). Conclusions The FDTC group displays distinct characteristics as increased aggressivess at diagnose and the worse response to ¹³¹I therapy.